Miller-Fisher Syndrome Presenting With Severe Headache and Transient Loss of Consciousness: A Case Report From Yemen

Abstract

Background

Miller-Fisher syndrome (MFS) is a rare variant of Guillain-Barré syndrome (GBS), characterized by the classic triad of ataxia, areflexia, and ophthalmoplegia. Atypical presentations involving severe headache and transient loss of consciousness (LOC) are extremely rare, posing a significant diagnostic challenge.

Case presentation

We present a 38-year-old Yemeni female with hypertension, type II diabetes mellitus, and recurrent deep vein thrombosis, with no history of recent infection. She presented with an acute, severe headache lasting three days, followed by transient LOC. By the fourth day, the classic MFS triad emerged. In a resource-limited setting, diagnosis was based on the clinical triad and evidence of demyelinating polyneuropathy on nerve conduction studies (NCS), in the absence of anti-GQ1b antibody testing and normal brain neuroimaging. After receiving intravenous immunoglobulin (IVIG), the headache resolved significantly by the third dose. The patient showed improvement in ophthalmoplegia and ptosis, achieving complete neurological recovery within two months.

Conclusion

Acute severe headache and transient LOC can be an early, atypical manifestation of MFS. The clinical triad and electrophysiology findings remain the cornerstones of diagnosis when antibody testing is unavailable. Early intervention with IVIG led to a successful outcome.

Keywords

miller-Fisher syndrome guillain-barré syndrome atypical presentation headache loss of consciousness IVIG

Introduction

Miller Fisher Syndrome (MFS) is a rare subtype of Guillain-Barré Syndrome (GBS), characterized as an acute, immune-mediated neuropathy that primarily affects the peripheral nervous system.¹ MFS typically presents with the classic diagnostic triad of ophthalmoplegia, ataxia, and areflexia.² While first described by Collier in 1932 and later formally characterized by Miller Fisher in 1956, its pathogenesis is largely attributed to molecular mimicry involving anti-GQ1b antibodies. The global incidence of MFS is 1–2 per 100,000.^1,3,4 Although MFS often follows a prodromal infection, atypical presentations can emerge idiopathically, manifesting as unusual symptoms that challenge standard diagnostic criteria.^3,5,6 The occurrence of acute severe headache and transient loss of consciousness (LOC) is extremely rare in MFS and often misleads clinicians toward vascular or central nervous system pathologies, such as stroke or hypertensive emergencies. Here, we report a case of a 38-year-old female whose initial presentation was dominated by severe headache and LOC. This case highlights the importance of clinical vigilance in identifying MFS when it is masked by atypical neurological symptoms, particularly in resource-limited settings where specialized serological testing may be unavailable.

Case Presentation

A 38-year-old Yemeni female presented to the Emergency Department on December 20, 2025, with an acute onset of severe headache for three days, followed by transient loss of consciousness. Her medical history was significant for long-standing hypertension of 9 years duration, type II diabetes mellitus of 8 years duration, and deep vein thrombosis (DVT), with the most recent documented recurrence in September 2025.

The patient had been clinically stable until three days prior to ICU admission, when she developed a throbbing occipital headache that was refractory to high-dose analgesics (Paracetamol Extra 3000 mg/day). On the third day, she experienced a transient LOC lasting 15 minutes. Notably, there was no post-ictal confusion, and the patient achieved a Glasgow Coma Scale (GCS) of 15/15 immediately upon regaining consciousness, which strongly argued against a prolonged post-ictal state or hypertensive encephalopathy.

Initial assessment at the primary healthcare center revealed significant hypertension (200/110 mmHg), tachycardia (120 bpm), tachypnea (25 breaths/min), and a temperature of 37.5°C. Upon regaining consciousness, the patient presented with acute painful bilateral ophthalmoplegia, bilateral complete ptosis, and blurred vision. Brain MRI and MRV detected no evidence of acute or chronic venous sinus thrombosis, with no filling defects identified. Furthermore, the absence of intracranial or orbital lesions effectively ruled out space-occupying lesions or vascular causes for the patient’s symptoms. The absence of T2/FLAIR hyperintensities in posterior circulation ruled out Posterior Reversible Encephalopathy Syndrome (PRES) despite the hypertensive urgency. Echocardiography (Echo) showed concentric left ventricular hypertrophy (LVH) with impaired diastolic filling; however, the ejection fraction (EF) was preserved (59%). There was no evidence of mural thrombi, vegetations, or segmental wall motion abnormalities. Although a lumbar puncture (LP) was indicated, the patient initially refused and left the hospital against medical advice.

By the fourth day of disease course, her condition deteriorated significantly, progressing to neck extensor weakness “dropped head sign”, acute ascending motor paralysis, and distal paresthesia sensations. Given the rapid clinical decline and the high risk of respiratory failure, the patient was urgently admitted and transferred to Intensive Care Unit (ICU) for stabilization and definitive management. Upon ICU admission, physical examination revealed profound quadriparesis (Motor power: 2/5 in the upper limbs, 1/5 in the lower limbs), distal paresthesia, and complete bilateral ptosis. Generalized areflexia was confirmed in all four limbs, while plantar responses flexor (negative Babinski signs), localizing the pathology to peripheral nervous system (PNS) and making a central brainstem lesion unlikely. Due to severe quadriparesis, cerebellar testing, such as the finger-to-nose and heel-to-shin tests, could not be performed. Despite stable O2 saturation (≥94%), she developed mild respiratory distress and oropharyngeal dysphagia. Overflow urinary incontinence was also observed, suggesting autonomic instability, a recognized feature of the GBS spectrum.

Following an urgent neurological consultation, the classic MFS triad (ophthalmoplegia, ataxia, and areflexia) was identified. Comprehensive nerve conduction studies (NCS) were performed. The NCS of the left upper and lower extremities showed a definitive pattern of demyelinating polyneuropathy. Specifically, the motor NCS of the left median nerve exhibited a normal compound motor action potential (CMAP) and CV but with prolonged distal motor latency (DML) and temporal dispersion pattern (Figure 1A). In the lower limbs, the left peroneal nerve showed reduced CMAP amplitude with a marked temporal dispersion (Figure 1B), and the left tibial nerve exhibited a reduced CMAP amplitude with an absent proximal response. Furthermore, the left median nerve SNAP showed reduced amplitude, slowed conduction velocity (CV), and an absence of F-waves (Figure 1C) in initial trials, followed by persistent F-waves. Collectively, prolonged distal latency and dispersion in the median nerve, reduced peroneal CMAP with temporal dispersion, and the reduced tibial proximal response —electrophysiologically confirm a primary demyelinating process. The detailed quantitative parameters are summarized in (Table 1).

Figure 1.

NCS of the left Extremities: (A) Motor Nerve Conduction Study (NCS) of the Left Median Nerve showing prolonged distal latency (8.40 ms) with a prominent dispersion pattern (black arrow). (B) Left peroneal motor NCS demonstrating marked amplitude reduction and severe dispersion (red arrow). (C) Left median SNAP and F-waves study illustrating initial absent F-waves, followed by persistent F-waves with prolonged latency (blue arrows)

Table 1.

NCS Findings: Summary of Motor, Sensory, and F-Wave Demonstrating a Definitive Demyelinating Polyneuropathy

Motor nerve conduction study (NCS)
Motor	Lat.onset	Pk-amp	Tot. Area	Dist.	MCV	Normal reference
Motor	ms	mv	mv.ms	mm	m/s	Normal reference
Median nerve (Left)
Wrist-APB	8.40	4.55	18.70	50	-	Latency < 4.4 ms
Elbow-wrist	13.12	4.49	19.39	220	45.71	CV > 49 m/s
Ulnar nerve (Left)
Wrist-ADM	2.72	5.11	21.96	60	-	Latency < 3.3 ms
Below elbow-wrist	7.87	3.27	12.42	230	44.60	CV > 49 m/s
Tibial nerve (Left)
Median malleolus	5.93	2.22	11.71	0	-	Latency < 6.1 ms
Popliteal fossa - Median malleolus	9.58	0.74	5.11	0	-	Amp > 4.0 mV
Peroneal nerve (Left)
Ankle-EDB	6.10	2.03	8.76	100	-	Latency < 6.5 ms
Fibular head-ankle	11.78	0.86	3.40	280	49.37	CV > 44 m/s

Sensory nerve conduction study (NCS)
Sensory	Pk- amp	Dist.	Lat 1 pos	NCV	Normal reference
Sensory	ms	µV	mm	m/s	Normal reference
Median nerve (left)
Digit II-Wrist	3.691	28.10	100	20.38	NCV > 50 m/s

F-wave minimal latency and persistence results
F Wave	m-lat	F lat min	F disp	F%	Normal reference
F Wave	ms	ms	Ms	%	Normal reference
Wrist	7.25	19.99	19.44	100%	F-Lat< 31 ms

Note. Abbreviations: ADM: Abductor Digiti Minimi; APB: Abductor Pollicis Brevis; Dist: Distance; EDB: Extensor Digitorum Brevis; F disp:F-wave dispersion; F lat min: minimum F-wave latency; Lat: Latency; Lat 1 Pos: Onset Latency; MCV: Motor Conduction Velocity; M-lat: M-wave latency; NCV: Nerve Conduction Velocity; PK-amp: Peak Amplitude; Tot. Area: Total Area.

On second day of hospitalization, an ophthalmologist confirmed global painful ophthalmoplegia, with a prominent left-sided abducens paralysis resulting in exotropia. Visual acuity was severely impaired (limited to the perception of vague shapes). However, the preservation of bilateral pupillary light reflexes and unremarkable fundoscopic findings excluded optic nerve pathology and papilledema. These findings localized the deficit to total external ophthalmoplegia and accommodative failure, confirming a neuromuscular etiology rather than the sensory visual pathway or intracranial lesions. Laboratory investigations (Table 2) ruled out metabolic or infectious etiologies.

Table 2.

Initial Laboratory Investigations at Admission

Laboratory study	Measured values	Reference values
Complete blood count (CBC)
Hb	13.4	11.5-16.5 g/dL
RBC	5.04	4-5.2 x10 ¹²/L
WBC	5.92	4-11 X10³/µL
Platelets	268	150-450 X10³/µL
Renal function tests (RFT)
Serum creatinine	0.53	0-1.1 mg/dl
Blood urea	19	0-50 mg/dl
Liver function tests (LFT)
ALT	23	0-35 U/L
AST	19	0-35 U/L
Total bilirubin	0.30	0-1 mg/dl
Direct bilirubin	0.07	0- 0.3 mg/dl
Albumin	4.0	3.5-5.0 g/dl
Random blood sugar	156	74-140 mg/dl
HbA1C	9.0%	Non diabetic: > 6.0 Diabetic: <7.0
Serum vitamin B12	450	200-900 pg/ml
TSH	2.1	0.4-4.4Miu/L
Electrolytes Profile
Serum Na	136	132-152 mmol/L
Serum K	3.6	3.3-5.1 mmol/L
Serum Ca	9.1	8.8-10.5 mg/dl
Serum Mg	1.75	1.7-2.55 mg/dl
Coagulation profiles
PT	11.5	11-14 sec
INR	1.05
aPPT	35.0	25-35 sec
nflammatory markers
CRP	15	0-4 mg/l
Viral screening
HBsAg	Negative	Negative > 1.0
HBsAg	Negative	Positive < 1.0
HCV Ab	Negative	Negative > 1.0
HCV Ab	Negative	Positive < 1.0
HIV 1&2	Negative	Negative > 1.0
HIV 1&2	Negative	Positive < 1.0

Upon ICU admission, intravenous immunoglobulin (IVIG) therapy (0.4 g/kg/day for five days) was initiated. The treatment regimen also included daily IV methylcobalamin, oral thioctic acid (600 mg twice daily), and intensive physical therapy. To mitigate the high thrombotic risk-given the patient’s history of recurrent DVT and the potential for IVIG-induced hyperviscosity-she was maintained on prophylactic enoxaparin (4,000 IU/day) throughout the course.

A dramatic response was observed: the severe headache, previously refractory to all analgesics, resolved completely following the third IVIG dose, supporting an immune-mediated mechanism. Motor power was 3/5 and 1/5 in the upper and lower limbs, respectively. By the completion of the five-day course, motor power improved to 4/5 in the upper limbs and 2/5 in the lower limbs. Swallowing functions and urinary continence were fully restored. By the day of discharge, the patient’s clinical status exhibited a profound neurological recovery. She was able to walk with assistance, with upper limb strength reaching 5/5, lower limb strength improving to 3/5. Regained partial head posture control, and a moderate improvement in her bilateral ptosis was noted. Two months later after discharge, the patient showed complete resolution of her motor deficits. She was walking independently without any assistance, with muscle strength having fully reverted to 5/5 in all four limbs. Her bilateral ptosis had complete resolution, accompanied by a marked subjective improvement in vision. Clinical timeline of the case (Figure 2).

Figure 2.

Clinical timeline of the case

Discussion

MFS is an immune-mediated inflammatory demyelinating disorder of the peripheral nerves, typically diagnosed by the classic triad of ataxia, areflexia, and external ophthalmoplegia. It is a rare GBS variant with a global incidence of 1–2 per 100,000.^1,4 The prevalence of MFS is significantly higher in Asian populations (15-25%) compared to Western regions 1-7%. While the reasons for this disparity are not clearly understood, environmental triggers likely play a crucial role.^3,4 Although MFS is often preceded by a gastrointestinal or viral infection, its etiology can be idiopathic.^2,5,6 Similar to GBS, MFS typically manifests days following a specific infection caused by pathogens such as Campylobacter jejuni, Cytomegalovirus (CMV), and Epstein–Barr virus. Molecular mimicry is identified as the primary mechanism driving the disease. More than 90% of MFS patients have elevated serum anti-ganglioside antibody levels, specifically anti-GQ1b antibodies.⁶ Under the 2014 classification, MFS, Bickerstaff’s Brainstem Encephalitis (BBE), and the Pharyngeal-Cervical-Brachial (PCB) variant represent a clinical continuum.⁷ These conditions are categorized based on their overlapping clinical features.⁷ The complexity of the initial presentation posed a significant diagnostic challenge, and required several differential diagnoses to rule out various neurological and vascular etiologies.

The patient’s history of recurrent deep vein thrombosis (DVT) and severe headache initially suggested Cerebral Venous Sinus Thrombosis (CVST). However, it was ruled out through Magnetic Resonance Venography (MRV) which demonstrated an absence of filling defects. Similarly, despite a history of T2DM, the combination of bilateral painful ophthalmoplegia and generalized areflexia was inconsistent with diabetic mononeuropathy. Diabetic cranial nerve involvement typically spares the pupils and lacks the generalized loss of deep tendon reflexes.¹ Additionally, Myasthenia Gravis (MG) was ruled out as the patient’s ptosis lacked diurnal fluctuation. Furthermore, the progression to ascending palsy and generalized areflexia is inconsistent with neuromuscular junction disorders.⁸

The initial presentation of hypertensive crisis (200/110 mmHg) and transient LOC initially suggested an acute cerebrovascular event. However, the spontaneous resolution of LOC within 15 minutes, Glasgow Coma Scale (GCS) of 15/15, and the absence of focal neurological deficits made a permanent stroke unlikely. The transient LOC in our patient was likely a neurocardiogenic response to the agonizing “thunderclap” headache or a manifestation of acute autonomic dysfunction, rather than primary brainstem lesions, as evidenced by the rapid return to baseline cognition. Furthermore, normal renal function tests and the absence of acute kidney injury ruled out a typical hypertensive emergency.⁹

Moreover, the absence of vasogenic edema on MRI FLAIR sequences, despite the severe hypertension, effectively excluded Posterior Reversible Encephalopathy Syndrome (PRES).¹⁰

Bickerstaff’s Brainstem Encephalitis (BBE) was initially suspected; however, the absence of prolonged impairment of consciousness, hyperreflexia, Babinski’s sign, sensory impairment, along with the normal brain MRI, made BBE unlikely.^11,12 By physical examination revealed absent limb reflexes and ataxia while NCS finding indicated demyelinating polyneuropathy.¹³ In line with Nayak et al, our case aligns with documented seronegative BBE-MFS overlap presentations. Furthermore, the patient’s prompt response to IVIG, despite the unavailability of anti-GQ1b antibody testing, reinforces that clinical and NCS finding remains the gold standard in resource-limited settings.¹⁴

The patient also demonstrated features of pharyngeal-cervical-brachial (PCB) variant of GBS. PCB is a rare variant of GBS often characterized by axonal neuropathy. PCB presented with progressive oropharyngeal weakness, neck extensor muscle weakness “dropped head sign”, areflexia in the upper limbs, and minimal or no lower limb involvement.^15-17

Approximately 60% of patients with acute GBS have a subtype with autoantibodies against different glycolipids of gangliosides, which correlate with different subtypes of GBS.¹⁸ GQ1b and GT1a are the most antibodies associated with MFS where GT1a associated with PCB variant of GBS. Clinicians must maintain a high suspicion for bulbar involvement. Detailed history taking and physical examination are essential to identify potential overlaps as early as possible. Serum anti-GQ1b antibodies have been taken as a key biological marker for MFS. The GQ1b antigen is highly expressed in the oculomotor, trochlear, and abducens nerves, which are the major cause of ophthalmoplegia.¹⁹ When anti-GQ1b antibody tests are negative, it remains possible that pathogenic antibodies are present in low titers. Even at low titers, these antibodies can cause severe neuropathic damage which typical clinical manifestations occur despite negative serological result.²⁰

Our clinical observations align with the recent findings of Huang et al regarding the atypical presentation of Miller-Fisher Syndrome. A key contribution of our report is the correlation between our NCS findings and the serological evidence presented in their report. While Huang et al confirmed their diagnosis using anti-GQ1b antibody titers and CSF analysis, we established the diagnosis using NCS in a resource-limited setting.¹ The present of demyelination polyneuropathy in our patient (Table1 and Figure 1) provide a neurophysiological counterpart to the albuminocytological dissociation and antibody positivity reported by Huang et al. This synergy between different diagnostic modalities—serological in their report and NCS in ours—demonstrates that both approaches can reliably identify the same underlying neuropathic process. This is particularly evident when presenting with atypical symptoms, such as severe headache, and transient LOC.

Although our patient experienced a severe headache, this remains a rare and atypical manifestation of MFS.

However, Jung et al and Koga et al documented headache in 16% and 22% of cases, respectively, during the acute phase of MFS.^21,22 While the exact etiology of the headache remains unclear, however, several potential mechanisms have been suggested. (1) Increased intracranial pressure can cause headaches because elevated protein in the CSF may obstruct drainage pathways. However, the patient did not show clinical signs of intracranial hypertension, such as nausea or vomiting, and she refused a lumbar puncture (LP).²³ (2) In 1996, PRES syndrome was described, and several reports have since documented its overlap with GBS. While the underlying mechanism remains unclear, the hypothesis suggests that sudden increases in blood pressure, caused by autonomic instability, exceed the cerebrovascular autoregulatory threshold, leading to vasogenic oedema.¹⁰ (3) Moreover, the hypothesis of altered endothelial function has been suggested, especially in patients with autoimmune diseases. In addition to, several cytokines’ substances are released in GBS (tumor necrosis factor-α, interleukin-6, interferon-γ, and IL-17). These cytokines can cause endothelial dysfunction and alter vascular permeability, making the vessels more permeable to fluids.²⁴ (4) The role of antibody-mediated trigeminal vascular pain pathways has also been studied. Friedman et al, found that GD3 and GD1b antigens are expressed in all cranial nerves involving the trigeminal nerve, and ventral and dorsal roots of the spinal cord. These antibodies against gangliosides that can cause demyelination of spinal and cranial sensory nerves, serve to activating the trigeminal vascular pain pathways causing severe headache.²⁵ In our case, this mechanism cannot be proven due to the unavailability of antibody testing. Our patient suffered from severe headaches that did not respond to maximal analgesia, including a maximum dose of 3000 mg of paracetamol per day. Nonetheless, the significant relief of the severe headache following IVIG treatment supports the hypothesis of antibody-mediated activation of trigeminal vascular pain pathways. MFS is generally characterized by a good prognosis with a low mortality rate less than 5%.²⁶ Nevertheless, early initiation of treatment and rehabilitation is crucial to improving the patient’s condition and facilitating a return to baseline function. In our case, the patient showed significant improvement after IVIG administration. The diagnosis was confirmed based on clinical symptoms and NCS findings, despite the absence of antibody testing and the patient’s refusal to undergo a LP.

Diagnostic Limitations and Diagnostic Certainty

While our patient presented with the classic triad and electrophysiological evidence that firmly establishes the diagnosis of MFS within the GBS spectrum, the features suggestive of a Pharyngeal-Cervical-Brachial (PCB) or Bickerstaff’s Brainstem Encephalitis (BBE) overlap remain hypothesized. We acknowledge significant diagnostic limitations in our resource-limited setting. The patient’s refusal to undergo a lumbar puncture prevented CSF analysis, which limits our ability to exclude other infectious or inflammatory CNS processes. Furthermore, the unavailability of anti-GQ1b and other anti-ganglioside antibody testing dictates that our diagnosis inherently rests on the combination of the classic clinical triad, characteristic demyelinating features on NCS, and the exclusion of vascular mimics via neuroimaging.

Despite these limitations, fulfilling Level 2 of the Brighton Collaboration Criteria justified the prompt initiation of IVIG, which ultimately led to the patient’s full recovery.

Conclusion

Acute severe headache and transient loss of consciousness can be early, atypical manifestation of MFS. When these symptoms are immediately followed by acute ophthalmoplegia and supported by characteristic NCS findings, a diagnosis of MFS or its overlap variants should be strongly considered, even in the absence of anti-GQ1b antibody testing or CSF analysis. Although atypical MFS generally carries a favorable prognosis, this case highlights that early initiation of IVIG therapy and intensive rehabilitation are critical to preventing respiratory complications and ensuring a rapid return to baseline functions. Clinicians should maintain high vigilance for such neurological mimics in an emergency setting.

Methods

This work has been reported in line with the SCARE criteria.²⁷

Footnotes

Acknowledgment

We hope to thank SMSR Team Lab. for their efforts and bringing our team together.

ORCID iDs

Najeeba Al-Shaibani

Anas Al-Kubati

Consent for Publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying clinical data. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Author Contributions

SB. wrote a part of the manuscript. NA. wrote a part of the manuscript. A.A. wrote a part of the manuscript. All authors read and approved the final manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data Availability Statement

The data supporting the findings of this case report are included within the article.*

References

Huang

Lin

Huang

Yan

. Miller-Fisher syndrome presenting with headache and ophthalmoparesis: a case report and literature review. Front Med (Lausanne). 2025;12:1575696. doi:10.3389/fmed.2025.1575696. Published 2025 Sep 8.

Shahrizaila

Yuki

. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry. 2013;84(5):576-583. doi:10.1136/jnnp-2012-302824.

Fisher

. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57-65. doi:10.1056/NEJM195607122550201.

Bukhari

Taboada

. A Case of Miller Fisher Syndrome and Literature Review. Cureus. 2017;9(2):e1048. doi:10.7759/cureus.1048. Published 2017 Feb 22.

Truong

Conley

Ashurst

. Miller-Fisher Syndrome: A Case Report and Review of the Literature. Clin Pract Cases Emerg Med. 2020;4(4):653-655. doi:10.5811/cpcem.2020.7.48507.

Chiba

Kusunoki

Obata

Machinami

Kanazawa

. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology. 1993;43(10):1911-1917. doi:10.1212/wnl.43.10.1911.

GBS Classification Group; GBS Classification Group, GBS Classification Group Wakerley

Uncini

Yuki

, Guillain-Barré and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol. 2014;10(9):537-544. doi:10.1038/nrneurol.2014.138.

Yepishin

Allison

Kaminskas

Zagorski

Liow

. Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential Diagnosis. Hawaii J Med Public Health. 2016;75(7):196-199.

Williams

Mancia

Spiering

, et al. ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.

10.

Farmakidis

Inan

Milstein

Herskovitz

. Headache and Pain in Guillain-Barré Syndrome. Curr Pain Headache Rep. 2015;19(8):40. doi:10.1007/s11916-015-0508-x.

11.

Pantbalekundri

Acharya

Shukla

Kumar

Malali

. Bickerstaff's Brainstem Encephalitis and Miller Fisher Syndrome: A Rare Overlap. Cureus. 2024;16(2):e55000. doi:10.7759/cureus.55000. Published 2024 Feb 26.

12.

Matsumoto

Kobayashi

Tamura

Ohkawa

Sekine

. Miller Fisher syndrome with transient coma: comparison with Bickerstaff brainstem encephalitis. Brain Dev. 2002;24(2):98-101. doi:10.1016/s0387-7604(01)00409-0.

13.

Odaka

Yuki

Yamada

, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain. 2003;126(Pt 10):2279-2290. doi:10.1093/brain/awg233.

14.

Nayak

Sharma

Nagaraju

Prabhu

. Bickerstaff brainstem encephalitis-Miller-Fisher syndrome (BBE-MFS) overlap with negative anti-GQ1b serology. BMJ Case Rep. 2024;17(12):e261975. doi:10.1136/bcr-2024-261975. Published 2024 Dec 22.

15.

Hiew

Ramlan

Viswanathan

Puvanarajah

. Guillain-Barré Syndrome, variants & forms fruste: Reclassification with new criteria. Clin Neurol Neurosurg. 2017;158:114-118. doi:10.1016/j.clineuro.2017.05.006.

16.

Kartiko

Selim

. A Case of Pharyngeal-Cervical-Brachial Variant of Guillain-Barré Syndrome With Bilateral Glossopharyngeal Paralysis. Cureus. 2021;13(4):e14551. doi:10.7759/cureus.14551. Published 2021 Apr 18.

17.

Kumar

Garg

Bharti

Zutshi

. Double Trouble: Guillain-Barré Syndrome (GBS) Presenting as Overlapping Miller Fisher Syndrome (MFS) and Pharyngeal-Cervical-Brachial (PCB) Variant. Cureus. 2025;17(12):e98367. doi:10.7759/cureus.98367. Published 2025 Dec 3.

18.

Fan

Jin

Hao

, et al. Anti-ganglioside antibodies in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy in Chinese patients. Muscle Nerve. 2017;55(4):470-475. doi:10.1002/mus.25266.

19.

Chiba

Kusunoki

Obata

Machinami

Kanazawa

. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 1997;745(1-2):32-36. doi:10.1016/s0006-8993(96)01123-7.

20.

Zhang

Zhou

Sun

Han

Fang

. Miller-Fisher syndrome with positive anti-GD1b and anti-GM1 antibodies combined with multiple autoimmune antibodies: A case report. Medicine (Baltimore). 2023;102(34):e34969. doi:10.1097/MD.0000000000034969.

21.

Jung

Shin

, et al. Atypical clinical manifestations of Miller Fisher syndrome. Neurol Sci. 2019;40(1):67-73. doi:10.1007/s10072-018-3580-2.

22.

Koga

Yuki

Hirata

. Pain in Miller Fisher syndrome. J Neurol. 2000;247(9):720-721. doi:10.1007/s004150070122.

23.

Mewasingh

Sékhara

Dachy

Djeunang

Dan

. Benign intracranial hypertension: atypical presentation of Miller Fisher syndrome? Pediatr Neurol. 2002;26(3):228-230. doi:10.1016/s0887-8994(01)00362-9.

24.

Sun

Chen

Shi

Liu

Cheng

. Peripheral Blood and Cerebrospinal Fluid Cytokine Levels in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis. Front Neurosci. 2019;13:717. doi:10.3389/fnins.2019.00717. Published 2019 Jul 16.

25.

Friedman

Potts

. Headache associated with miller fisher syndrome. Headache. 2007;47(9):1347-1348. doi:10.1111/j.1526-4610.2007.00935.x.

26.

Yuki

. Fisher syndrome and Guillain-Barré syndrome: spectrum of post-infectious demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry. 2009;80(1):4-5. doi:10.1136/jnnp.2008.152439.

27.

Sohrabi C, Mathew G, Maria N , et al. The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines. International Journal of Surgery. Wolters Kluwer 2023;109(5):1136-1140. doi:10.1097/JS9.0000000000000373 (published on behalf of the International Journal of Surgery).